A A

References

  1. Australian Institute of Health and Welfare. Australian Cancer Incidence and Mortality (ACIM) Books: Breast Cancer. Canberra, 2016
  2. Harris PF, Remington PL, Trentham-Dietz A, et al. Prevalence and treatment of menopausal symptoms among breast cancer survivors. Journal of Pain and Symptom Management. 2002;23(6):501-509
  3. Vincent AJ. Management of menopause in women with breast cancer. Climacteric. 2015;18:1-12
  4. Hickey M, Emery LI, Gregson J, et al. The multidisciplinary management of menopausal symptoms after breast cancer. Menopause. 2010;17(4):727-733
  5. Mar Fan HG, Houédé-Tchen N, Chemerynsky I, et al. Menopausal symptoms in women undergoing chemotherapy-induced adn natural menopause: a prospetive controlled study. Annals of Oncology. 2010;21:983-987
  6. Rosenberg SM and Partridge AH. Premature menopause in young breast cancer: effects on quality of life and treatment interventions. J Thorac Dis. 2013;5(S1):S55-S61
  7. National Breast Cancer Centre. Clinical practice guidelines for the management of early breast cancer: Second edition. Canberra, ACT, 2001
  8. National Breast Cancer Centre. Clinical practice guidelines for the management and support of younger women with breast cancer. Camperdown, NSW, 2004
  9. Cancer Australia. Breast cancer and early menopause - a guide for younger women. Surry Hills, NSW, 2012
  10. Hillier S, Grimmer-Somers K, Merlin T, et al. FORM: An Australian method for formulating and grading recommendations in evidence-based clinical guidelines. BMC Medical Research Methodology. 2011;11:23
  11. National Health and Medical Research Council. NHMRC additional levels of evidence and grades for recommendations for developers of guidelines. 2009
  12. Hunter M, Battersby R and Whitehead M. Relationships between psychological symptoms, somatic complaints and menopausal status. Maturitas. 1986;8:217-228
  13. Gupta P, Sturdee W, Palin SL, et al. Menopausal symptoms in women treated for breast cancer: the prevalence and seveity of symptoms and their perceieved effects on quality of life. Climacteric. 2006;9:49-58
  14. Stearns V, Slack R, Greep N, et al. Paroxetine is an effective treatment for hot flashes: results from a prospective randomized clinical trial. J Clin Oncol. 2005;23(28):6919-30
  15. Loprinzi CL, Sloan JA, Perez EA, et al. Phase III evaluation of fluoxetine for treatment of hot flashes. J Clin Oncol. 2002;20(6):1578-83
  16. Kimmick GG, Lovato J, McQuellon R, et al. Randomized, double-blind, placebo-controlled, crossover study of sertraline (Zoloft) for the treatment of hot flashes in women with early stage breast cancer taking tamoxifen. Breast J. 2006;12(2):114-22
  17. Wu MF, Hilsenbeck SG, Tham YL, et al. The efficacy of sertraline for controlling hot flashes in women with or at high risk of developing breast cancer. Breast Cancer Res Treat. 2009;118(2):369-75
  18. Shams T, Firwana B, Habib F, et al. SSRIs for hot flashes: a systematic review and meta-analysis of randomized trials. Journal of General Internal Medicine. 2014;29(1):204-13
  19. Guthrie KA, LaCroix AZ, Ensrud KE, et al. Pooled Analysis of Six Pharmacologic and Nonpharmacologic Interventions for Vasomotor Symptoms. Obstetrics & Gynecology. 2015;126(2):413-422
  20. Boekhout AH, Vincent AD, Dalesio OB, et al. Management of hot flashes in patients who have breast cancer with venlafaxine and clonidine: a randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2011;29(29):3862-8
  21. Carpenter JS, Storniolo AM, Johns S, et al. Randomized, double-blind, placebo-controlled crossover trials of venlafaxine for hot flashes after breast cancer. Oncologist. 2007;12(1):124-35
  22. Buijs C, Mom CH, Willemse PH, et al. Venlafaxine versus clonidine for the treatment of hot flashes in breast cancer patients: a double-blind, randomized cross-over study. Breast Cancer Res Treat. 2009;115(3):573-80
  23. Loibl S, Schwedler K, von Minckwitz G, et al. Venlafaxine is superior to clonidine as treatment of hot flashes in breast cancer patients--a double-blind, randomized study. Ann Oncol. 2007;18(4):689-93
  24. Bordeleau L, Pritchard KI, Loprinzi CL, et al. Multicenter, randomized, cross-over clinical trial of venlafaxine versus gabapentin for the management of hot flashes in breast cancer survivors. J Clin Oncol. 2010;28(35):5147-52
  25. Walker EM, Rodriguez AI, Kohn B, et al. Acupuncture versus venlafaxine for the management of vasomotor symptoms in patients with hormone receptor-positive breast cancer: a randomized controlled trial. J Clin Oncol. 2010;28(4):634-40
  26. Joffe H, Guthrie KA, LaCroix AZ, et al. Randomized Controlled Trial of Low-Dose Estradiol and the SNRI Venlafaxine for Vasomotor Symptoms. JAMA Intern Med. 2014;174(7):1058–1066
  27. Sun Z, Hao Y and M Z. Efficacy and safety of desvenlafaxine treatment for hot flashes associated with menopause: a meta-analysis of randomized controlled trials. Gynecologic and Obstetric Investigation. 2013;75(4):255-62
  28. Berhan Y and Berhan A. Is desvenlafaxine effective and safe in the treatment of menopausal vasomotor symptoms? A meta-analysis and meta-regression of randomized double-blind controlled studies. Ethiopian Journal of Health Science. 2014;24(3):209-18
  29. Nunez GR, Pinczowski H, Zanellato R, et al. Bupropion for control of hot flashes in breast cancer survivors: a prospective, double-blind, randomized, crossover, pilot phase II trial. J Pain Symptom Manage. 2013;45(6):969-79
  30. Joffe H, Partridge A, Giobbie-Hurder A, et al. Augmentation of venlafaxine and selective serotonin reuptake inhibitors with zolpidem improves sleep and quality of life in breast cancer patients with hot flashes: a randomized, double-blind, placebo-controlled trial. Menopause. 2010;17(5):908-16
  31. Pandya KJ, Morrow GR, Roscoe JA, et al. Gabapentin for hot flashes in 420 women with breast cancer: a randomised double-blind placebo-controlled trial. Lancet. 2005;366(9488):818-24
  32. Ahimahalle TZ, Ahmadi AS, Arabi M and Rahmani L. Clinical comparison of the effects of gabapentin and Megestrol acetate on hot flashes in patients with breast cancer. International Journal of Hematology-Oncology and Stem Cell Research. 2012;6(1):6-10
  33. Biglia N, Sgandurra P, Peano E, et al. Non-hormonal treatment of hot flushes in breast cancer survivors: gabapentin vs. vitamin E. Climacteric. 2009;12(4):310-8
  34. Kenemans P, Bundred NJ, Foidart JM, et al. Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial. Lancet Oncol. 2009;10(2):135-46
  35. Sismondi P, Kimmig R, Kubista E, et al. Effects of tibolone on climacteric symptoms and quality of life in breast cancer patients--data from LIBERATE trial. Maturitas. 2011;70(4):365-72
  36. Frisk J, Carlhall S, Kallstrom AC, et al. Long-term follow-up of acupuncture and hormone therapy on hot flushes in women with breast cancer: a prospective, randomized, controlled multicenter trial. Climacteric. 2008;11(2):166-74
  37. Frisk J, Kallstrom AC, Wall N, et al. Acupuncture improves health-related quality-of-life (HRQoL) and sleep in women with breast cancer and hot flushes. Support Care Cancer. 2012;20(4):715-24
  38. Formoso G, Perrone E, Maltoni S, et al. Short and long term effects of tibolone in postmenopausal women. Cochrane Database of Systematic Reviews. 2012;2:CD008536
  39. Maclennan AH, Broadbent JL, Lester S and Moore V. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database of Systematic Reviews. 2009;4:CD002978
  40. Corbelli J, Shaikh N, Wessel C and Hess R. Low-dose transdermal estradiol for vasomotor symptoms: a systematic review. Menopause. 2015;22(1):114-21
  41. Derzko C, Sergerie M, Siliman G, et al. Comparative efficacy and safety of estradiol transdermal preparations for the treatment of vasomotor symptoms in postmenopausal women: an indirect comparison meta-analysis. Menopause. 2016;23(3):294-303
  42. Whelan AM, Jurgens TM and Trinacty M. Bioidentical progesterone cream for menopause-related vasomotor symptoms: is it effective? Ann Pharmacother. 2013;47(1):112-6
  43. Cui Y, Zong H, Yan H, et al. The efficacy and safety of ospemifene in treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy: a systematic review and meta-analysis. Journal of Sexual Medicine. 2014;11(2):487-97
  44. Somboonporn W, Davis S, Seif MW and Bell R. Testosterone for peri- and postmenopausal women. Cochrane Database Syst Rev. 2005;4:CD004509
  45. Mann E, Smith MJ, Hellier J, et al. Cognitive behavioural treatment for women who have menopausal symptoms after breast cancer treatment (MENOS 1): a randomised controlled trial. Lancet Oncol. 2012;13(3):309-18
  46. Duijts SF, van Beurden M, Oldenburg HS, et al. Efficacy of cognitive behavioral therapy and physical exercise in alleviating treatment-induced menopausal symptoms in patients with breast cancer: results of a randomized, controlled, multicenter trial. J Clin Oncol. 2012;30(33):4124-33
  47. Velez Toral M, Godoy-Izquierdo D, Padial Garcia A, et al. Psychosocial interventions in perimenopausal and postmenopausal women: a systematic review of randomised and non-randomised trials and non-controlled studies. Maturitas. 2014;77(2):93-110
  48. Elkins G, Marcus J, Stearns V, et al. Randomized trial of a hypnosis intervention for treatment of hot flashes among breast cancer survivors. J Clin Oncol. 2008;26(31):5022-6
  49. Hervik J and Mjaland O. Acupuncture for the treatment of hot flashes in breast cancer patients, a randomized, controlled trial. Breast Cancer Res Treat. 2009;116(2):311-6
  50. Deng G, Vickers A, Yeung S, et al. Randomized, controlled trial of acupuncture for the treatment of hot flashes in breast cancer patients. J Clin Oncol. 2007;25(35):5584-90
  51. Liljegren A, Gunnarsson P, Landgren BM, et al. Reducing vasomotor symptoms with acupuncture in breast cancer patients treated with adjuvant tamoxifen: a randomized controlled trial. Breast Cancer Res Treat. 2012;135(3):791-8
  52. Bokmand S and Flyger H. Acupuncture relieves menopausal discomfort in breast cancer patients: a prospective, double blinded, randomized study. Breast. 2013;22(3):320-3
  53. Nedstrand E, Wijma K, Wyon Y and Hammar M. Vasomotor symptoms decrease in women with breast cancer randomized to treatment with applied relaxation or electro-acupuncture: a preliminary study. Climacteric. 2005;8(3):243-50
  54. Nedstrand E, Wyon Y, Hammar M and Wijma K. Psychological well-being improves in women with breast cancer after treatment with applied relaxation or electro-acupuncture for vasomotor symptom. J Psychosom Obstet Gynaecol. 2006;27(4):193-9
  55. Mao JJ, Bowman MA, Xie SX, et al. Electroacupuncture Versus Gabapentin for Hot Flashes Among Breast Cancer Survivors: A Randomized Placebo-Controlled Trial. Journal of Clinical Oncology. 2015;33(31):3615-3620
  56. Dodin S, Blanchet C, Marc I, et al. Acupuncture for menopausal hot flushes. Cochrane Database Syst Rev. 2013;7:CD007410
  57. Ee C, Xue C, Chondros P, et al. Acupuncture for Menopausal Hot Flashes: A Randomized Trial. Ann Intern Med. 2016;164(3):146-54
  58. Fenlon DR, Corner JL and Haviland JS. A randomized controlled trial of relaxation training to reduce hot flashes in women with primary breast cancer. J Pain Symptom Manage. 2008;35(4):397-405
  59. Saensk S, Vutyavanich T, Somboonporn W and M S. Relaxation for perimenopausal and postmenopausal symptoms (Review). The Cochrane Collaboration. 2014;7:CD008582
  60. Carson JW, Carson KM, Porter LS, et al. Yoga of Awareness program for menopausal symptoms in breast cancer survivors: results from a randomized trial. Support Care Cancer. 2009;17(10):1301-9
  61. Cramer H, Rabsilber S, Lauche R, et al. Yoga and Meditation for Menopausal Symptoms in Breast Cancer Survivors—A Randomized Controlled Trial. Cancer. 2015;121:2175-2184.
  62. Newton KM, Reed SD, Guthrie KA, et al. Efficacy of Yoga for Vasomotor Symptoms: A Randomized Controlled Trial. Menopause. 2014;21(4):339–346
  63. Woods NF, Mitchell ES, Schnall JG and al e. Effects of mind-body therapies on symptom clusters during the menopasal transition. Climacteric. 2014;17(1):10-22
  64. Daley A, Stokes-Lampard H, Thomas A and MacArthur C. Exercise for vasomotor menopausal symptoms. Cochrane Database of Systematic Reviews. 2014;11:CD006108
  65. Sternfeld B, Guthrie KA, Ensrud KE, et al. Efficacy of exercise for menopausal symptoms: a randomized controlled trial. Menopause. 2014;21(4):330-338
  66. Pockaj BA, Gallagher JG, Loprinzi CL, et al. Phase III double-blind, randomized, placebo-controlled crossover trial of black cohosh in the management of hot flashes: NCCTG Trial N01CC1. J Clin Oncol. 2006;24(18):2836-41
  67. Jacobson JS, Troxel AB, Evans J, et al. Randomized trial of black cohosh for the treatment of hot flashes among women with a history of breast cancer. J Clin Oncol. 2001;19(10):2739-45
  68. Hernandez Munoz G and Pluchino S. Cimicifuga racemosa for the treatment of hot flushes in women surviving breast cancer. Maturitas. 2003;44 Suppl 1:S59-65
  69. Leach MJ and V M. Black cohosh (Cimicifuga spp.) for menopausal symptoms. Cochrane Database of Systematic Reviews. 2012;9:CD007244
  70. Thompson EA, Montgomery A, Douglas D and Reilly D. A pilot, randomized, double-blinded, placebo-controlled trial of individualized homeopathy for symptoms of estrogen withdrawal in breast-cancer survivors. J Altern Complement Med. 2005;11(1):13-20
  71. Jacobs J, Herman P, Heron K, et al. Homeopathy for menopausal symptoms in breast cancer survivors: a preliminary randomized controlled trial. J Altern Complement Med. 2005;11(1):21-7
  72. Nikander E, Kilkkinen A, Metsa-Heikkila M, et al. A randomized placebo-controlled crossover trial with phytoestrogens in treatment of menopause in breast cancer patients. Obstet Gynecol. 2003;101(6):1213-20
  73. Van Patten CL, Olivotto IA, Chambers GK, et al. Effect of soy phytoestrogens on hot flashes in postmenopausal women with breast cancer: a randomized, controlled clinical trial. J Clin Oncol. 2002;20(6):1449-55
  74. MacGregor CA, Canney PA, Patterson G, et al. A randomised double-blind controlled trial of oral soy supplements versus placebo for treatment of menopausal symptoms in patients with early breast cancer. Eur J Cancer. 2005;41(5):708-14
  75. Thomas AJ, Ismail R, Taylor-Swanson L, et al. Effects of isoflavones and amino acid therapies for hot flashes and co-occurring symptoms during the menopausal transition and early postmenopause: a systematic review. Maturitas. 2014;78(4):263-76
  76. Cohen LS, Joffe H, Guthrie KA, et al. Efficacy of Omega-3 Treatment for Vasomotor Symptoms: A Randomized Controlled Trial: Omega-3 treatment for vasomotor symptoms. Menopause. 2014;21(4):347–354
  77. Carpenter JS, Wells N, Lambert B, et al. A pilot study of magnetic therapy for hot flashes after breast cancer. Cancer Nurs. 2002;25(2):104-9
  78. Fahlen M, Wallberg B, von Schoultz E, et al. Health-related quality of life during hormone therapy after breast cancer: a randomized trial. Climacteric. 2011;14(1):164-70
  79. Matthews EE, Berger AM, Schmiege SJ, et al. Cognitive Behavioral Therapy for Insomnia Outcomes in Women After Primary Breast Cancer Treatment: A Randomized, Controlled Trial. Oncology Nursing Forum. 2014;41(3):241-253
  80. Lee YK, Chung HH, Kim JW, et al. Vaginal pH-balanced gel for the control of atrophic vaginitis among breast cancer survivors: a randomized controlled trial. Obstet Gynecol. 2011;117(4):922-7
  81. Goetsch MF, Lim JY and Caughey AB. A Practical Solution for Dyspareunia in Breast Cancer Survivors: A Randomized Controlled Trial. Journal of Clinical Oncology. 2015;33(30):3394-3402
  82. Marsden J, Baum M, A'Hern RA, et al. The impact of hormone replacement therapy on breast cancer patients' quality of life and sexuality: a pilot study. Menopause International. 2001;7:85-91
  83. Reed SD, Mitchell CM, Joffe H, et al. Sexual function in women on estradiol or venlafaxine for hot flushes. Obstetrics and Gynecology. 2014;124(2):233-241
  84. Nastri C, Lara L, Ferriani R, et al. Hormone therapy for sexual function in perimenopausal and postmenopausal women. Cochrane Database of Systematic Reviews. 2013;6:CD009672
  85. Suckling J, Kennedy R, Lethaby A and Robertis H. Local oestrogen for vaginal atrophy in postmenopausal women. The Cochrane Collaboration. 2006;(4)
  86. Rahn DD, Carberry C, Sanses TV, et al. Vaginal Estrogen for Genitourinary Syndrome of Menopause: A Systematic Review. The American College of Obstetricians and Gynecologists. 2014;124(6):1147-1156
  87. Elraiyah T, Sonbol MB, Wang Z, et al. Clinical review: The benefits and harms of systemic testosterone therapy in postmenopausal women with normal adrenal function: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2014;99(10):3543-50
  88. Ghazanfarpour M, Sadeghi R and Latifnejad Roudsari R. The application of soy isoflavones for subjective symptoms and objective signs of vaginal atrophy in menopause: A systematic review of randomised controlled trials. Journal of Obstetrics and Gynaecology. 2015;35:1364-6893
  89. Lavigne JE, Heckler C, Mathews JL, et al. A randomized, controlled, double-blinded clinical trial of gabapentin 300 versus 900 mg versus placebo for anxiety symptoms in breast cancer survivors. Breast Cancer Res Treat. 2012;136(2):479-86
  90. Holmberg L and Anderson H. HABITS (hormonal replacement therapy after breast cancer - is it safe?), a randomised comparison: trial stopped. The Lancet. 2004;363:453-455
  91. von Schoultz E, Rutqvist LE and Stockholm Breast Cancer Group. Menopausal hormone therapy after breast cancer: the Stockholm randomized trial. Journal of the National Cancer Institute. 2005;97(7):533-535
  92. Barton DL, Wender DB, Sloan JA, et al. Randomized controlled trial to evaluate transdermal testosterone in female cancer survivors with decreased libido. J Natl Cancer Inst. 2007;99(9):672-9
  93. Velentzis LS, Banks E, Sitas F, et al. Use of Menopausal Hormone Therapy and Bioidentical Hormone Therapy in Australian Women 50 to 69 Years of Age: Results from a National, Cross-Sectional Study. PLoS One. 2016;23(11):3
  94. Zerbinati N, Serati M, Origoni M, et al. Microscopic and ultrastructural modifications of postmenopausal atrophic vaginal mucosa after fractional carbon dioxide laser treatment. Lasers Med Sci. 2015;30(1):429-36
  95. Salvatore S, Leone Roberti Maggiore U, Athanasiou S, et al. Histological study on the effects of microablative fractional CO2 laser on atrophic vaginal tissue: an ex vivo study. Menopause. 2015;22(8):845-9
  96. Salvatore S, Nappi RE, Zerbinati N, et al. A 12-week treatment with fractional CO2 laser for vulvovaginal atrophy: a pilot study. Climacteric. 2014;17(4):363-9
  97. Perino A, Calligaro A, Forlani F, et al. Vulvo-vaginal atrophy: a new treatment modality using thermo-ablative fractional CO2 laser. Maturitas. 2015;80(3):296-301
  98. Salvatore S, Nappi RE, Parma M, et al. Sexual function after fractional microablative CO₂ laser in women with vulvovaginal atrophy. Climacteric. 2015;18(2):219-25.
  99. Bradford A. Listening to placebo in clinical trials for female sexual dysfunction. J Sex Med. 2013;10(2):451-9
  100. Hickey M, Marino JL, Braat S and Wong S. A randomized, double-blind, crossover trial comparing a silicone- versus water-based lubricant for sexual discomfort after breast cancer. Breast Cancer Res Treat. 2016;158(1):79-90
  101. Australian Government Department of Health. Therapeutic Goods Administration. http://www.tga.gov.au/. Accessed: August 2016.
  102. Freeman EW, Guthrie KA, Sternfeld B, et al. Efficacy of escitalopram for hot flashes in healthy menopsual women: a randomized controlled trial. JAMA. 2011;305(3):267-274